Veltuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD20 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
728917-18-8  |
| ChemSpider | none |
| UNII |
BPD4DGQ314  |
| Chemical and physical data | |
| Formula | C6458H9918N1706O2026S46 |
| Molar mass | 145.3 kg/mol |
| (what is this?) (verify) | |
Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]
See also
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- ↑ Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C. -H. (2009). "CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491
. PMID 19710501. - ↑ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- ↑ The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
- ↑ Handbook of Therapeutic Antibodies. p791
- 1 2 FDA grants orphan drug designation to veltuzumab for ITP
This article is issued from Wikipedia - version of the 9/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.